Last reviewed · How we verify
Corynebacterium granulosum P40
Corynebacterium granulosum P40 is a bacterial immunotherapeutic that stimulates anti-tumor immune responses through activation of innate and adaptive immunity.
Corynebacterium granulosum P40 is a bacterial immunotherapeutic that stimulates anti-tumor immune responses through activation of innate and adaptive immunity. Used for Cancer immunotherapy (specific indications in Phase 3 trials not publicly detailed).
At a glance
| Generic name | Corynebacterium granulosum P40 |
|---|---|
| Sponsor | Centro Oncologico de Excelencia |
| Drug class | Bacterial immunotherapy / Cancer vaccine |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This is a live attenuated strain of Corynebacterium granulosum designed to act as an immunological adjuvant. It works by triggering pattern recognition receptors on immune cells, promoting dendritic cell maturation and T-cell activation to enhance anti-tumor immunity. The mechanism leverages bacterial cell wall components to generate both innate inflammatory responses and adaptive immune memory against tumor-associated antigens.
Approved indications
- Cancer immunotherapy (specific indications in Phase 3 trials not publicly detailed)
Common side effects
- Local injection site reactions
- Fever
- Fatigue
- Flu-like symptoms
Key clinical trials
- Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Corynebacterium granulosum P40 CI brief — competitive landscape report
- Corynebacterium granulosum P40 updates RSS · CI watch RSS
- Centro Oncologico de Excelencia portfolio CI